<DOC>
	<DOCNO>NCT00630149</DOCNO>
	<brief_summary>This pilot phase II study locally advance metastatic nasopharyngeal carcinoma ( NPC ) single drug Alimta . The objective study ass efficacy safety profile Alimta 2nd line treatment patient advance NPC .</brief_summary>
	<brief_title>Study Alimta Patients With Recurrent Metastatic Nasopharyngeal Carcinoma ( NPC ) Who Have Had Prior Platinum Based Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Histologic diagnosis nasopharyngeal carcinoma . Locally recurrent metastatic disease . Patients must previously receive one platinum base chemotherapy regimen palliative therapy locally advance metastatic disease . Prior platinum base chemotherapy complete least 3 month prior study enrollment patient must recover toxic effect treatment . Previous radiation therapy allow , limited must include whole pelvis radiation . Patients must recover toxic effect treatment prior study enrollment ( except alopecia ) . Prior radiotherapy must complete 30 day study entry . Lesions radiate included site measurable disease unless clear tumor progression document lesion since end radiation therapy . Disease status must measurable disease define Response Evaluation Criteria Solid Tumors ( RECIST ) criterion . Performance status 0 1 Eastern Cooperative Oncology Group ( ECOG ) Scale . Estimated life expectancy least 8 week . Patient compliance geographic proximity allow adequate followup . Adequate organ function include follow : Bone marrow : absolute neutrophil count ( ANC ) &gt; or= 1.5x10^9/L , platelet &gt; or= 100x10^9/L , hemoglobin &gt; or= 9g/dL . Hepatic : bilirubin &lt; 1.5 x ULN , alkaline phosphatase , aspartate transaminase ( AST ) alanine transaminase ( ALT ) &lt; 2.5 x ULN ( alkaline phosphatase , AST , ALT &lt; 5 x ULN acceptable liver tumor involvement ) . Renal : calculated creatinine clearance &gt; 45 ml/min . Men woman least 18 year age . For woman : Must surgically sterile , postmenopausal , compliant medically approve contraceptive regimen 3 month treatment period ; must negative serum urine pregnancy test must lactate . For men : Must surgically sterile , compliant contraceptive regimen 3 month treatment period . Signed informed consent patient . Known suspected brain metastasis . Patients clinical sign symptoms suspicious brain metastasis must pretreatment compute tomography ( CT ) magnetic resonance imaging ( MRI ) brain . A patient document brain metastasis , time consideration study entry past , exclude enter study . Have previously complete withdrawn study , receive Alimta previously outside study . Concurrent administration tumor therapy . Active infection ( discretion investigator ) . Serious concomitant disorder would compromise safety patient compromise patient 's ability complete study , discretion investigator . Pregnancy breast feed . History significant neurological mental disorder , include seizure dementia . Second primary malignancy clinically detectable time consideration study enrollment . Have receive treatment within last 30 day drug receive regulatory approval indication time study entry . Inability interrupt aspirin nonsteroidal antiinflammatory drug ( NSAIDs ) 2 day , day , 2 day dose Alimta . If patient take NSAID ( Cox2 inhibitor include ) salicylate long halflife , take 5 day , day , 2 day dose Alimta . Presence clinically relevant thirdspace fluid collection control drainage procedure prior study entry . Inability unwillingness take folic acid , vitamin B12 supplementation , dexamethasone .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Nasopharyngeal Neoplasms</keyword>
	<keyword>Pemetrexed</keyword>
</DOC>